CARE (Corona Accelerated R&D in Europe) aims to create effective therapies with a positive safety profile and develop new drugs and antibodies specifically designed to tackle the virus. Its strategy is based on three core pillars: Drug repositioning, by screening and profiling compound libraries contributed by partners with the aim of rapidly progressing molecules to advanced stages of clinical testing; small-molecule drug discovery based on in silico screening and profiling of candidate compounds directed against SARS-CoV-2 and future coronavirus targets; and virus-neutralising antibody discovery using fully human phage and yeast display, immunisation of humanised animal models, patient B cells and in silico design. The most promising candidates will be advanced into Phase 1 and Phase 2 clinical trials in humans. CARE and all of its members are dedicated to winning the fight against COVID-19 and CORDIS will of course aim to regularly provide its readers with updates on the project’s progress as it happens! For more information please see: https://cordis.europa.eu/project/id/101005077 “Beyond the scientific excellence of the different teams involved in this very ambitious project, CARE is bringing together 37 partners in an alliance pooling their expertise and know-how around an ambitious 5-year work plan to develop therapeutics against the current COVID-19 pandemic.” - Yves Lévy, CARE project coordinator If you are interested in having your project featured in ‘Project of the Month’ in an upcoming issue, please send us an email to email@example.com and tell us why!
CARE, COVID-19, SARS-CoV-2, drug repositioning, antibodies